```html

Nitisinone‑Induced Tyrosinemia Type I

Overview

Tyrosinemia type I (HT‑1) is a rare inherited disorder of amino‑acid metabolism caused by deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). The disease leads to accumulation of toxic metabolites that damage the liver, kidneys, and peripheral nerves. In 1994 the drug nitisinone (NTBC) was introduced as a specific inhibitor of 4‑hydroxyphenylpyruvate dioxygenase, dramatically improving survival. Paradoxically, long‑term NTBC therapy can itself cause a secondary metabolic disturbance known as **nitisinone‑induced tyrosinemia**. This guide explains the condition, its presentation, and how to manage it.

Who it affects: HT‑1 is autosomal recessive, affecting males and females equally. It occurs in <sup>1</sup> / 100,000 to 1 / 200,000 live births worldwide, with higher incidence in certain isolated populations (e.g., Iceland, the French‑Canadian Saguenay‑Lac‑Saint‑Jean region). The secondary tyrosinemia appears only in patients who are already on NTBC, regardless of age.

Prevalence of nitisinone‑induced tyrosinemia: Among patients receiving NTBC, up to 80 % develop elevated plasma tyrosine levels (>500 µmol/L), while 10–20 % develop clinically significant symptoms that require intervention <sup>[2]</sup>. Early detection and dietary control have reduced the number of severe cases.

Symptoms

Symptoms arise from two mechanisms:

1. Accumulation of **tyrosine** (hyper‑tyrosinemia) leading to ocular and dermatologic problems.
2. Persistent low‑level toxic metabolites when NTBC dosing is inadequate, potentially mimicking untreated HT‑1.

Ocular Manifestations

• Photophobia – sensitivity to bright light due to corneal deposits.
• Corneal keratopathy – whitish, gritty deposits that cause irritation and reduced visual acuity.
• Retinal pigmentary changes – rare, may affect color vision.

Dermatologic Manifestations

• Dermatitis – itchy, erythematous rash, often in flexural areas.
• Hyperpigmentation – darkening of skin, especially on sun‑exposed sites.
• Acne‑like eruptions – papulopustular lesions that may be mistaken for teenage acne.

Neurologic and Musculoskeletal Symptoms

• Headache – reported in up to 30 % of patients with high tyrosine.
• Fatigue & lethargy – due to impaired neurotransmitter synthesis.
• Ataxia or tremor – rare, linked to very high plasma tyrosine (>1500 µmol/L).

Gastrointestinal & Metabolic Symptoms

• Loss of appetite and early satiety.
• Nausea or vomiting – especially when dietary protein is abruptly increased.
• Weight loss or failure to thrive in children.

Signs of Inadequate NTBC (Persistent FAH Substrate Accumulation)

• Hepatomegaly or liver tenderness.
• Jaundice.
• Dark urine (due to succinylacetone).
• Renal tubular dysfunction (polyuria, electrolyte loss).

Causes and Risk Factors

NTBC itself does not cause a genetic defect; it blocks the conversion of 4‑hydroxyphenylpyruvate to homogentisic acid, causing a controlled rise in plasma tyrosine. The risk of symptomatic tyrosinemia depends on:

• Dosage and adherence – higher NTBC doses (>1 mg/kg/day) or missed doses increase tyrosine levels.
• Dietary protein intake – excess natural protein raises tyrosine load.
• Age – infants and young children have lower capacity to excrete excess tyrosine.
• Renal impairment – reduces clearance of tyrosine.
• Genetic variations in tyrosine metabolism enzymes (e.g., TAT, HPD) may modify susceptibility, though data are limited.

Diagnosis

Recognition relies on a combination of laboratory monitoring, clinical assessment, and imaging when needed.

Laboratory Tests

• Plasma tyrosine concentration – measured fasting; target < 500 µmol/L in NTBC‑treated patients (some centers aim for < 300 µmol/L).
• Succinylacetone (SA) – a specific biomarker for untreated HT‑1; low/undetectable levels confirm adequate NTBC inhibition.
• Liver function tests (ALT, AST, GGT, bilirubin) – to rule out hepatic decompensation.
• Renal panel (creatinine, electrolytes) – monitor tubular function.
• Complete blood count – to detect anemia or thrombocytopenia.

Imaging & Specialized Exams

• Ophthalmologic slit‑lamp exam – identifies corneal deposits.
• Abdominal ultrasound – assesses liver size, focal lesions, and kidney echogenicity.
• MRI (liver) – reserved for suspicious masses.

Monitoring Schedule

Age Group	Plasma Tyrosine	SA	Frequency
Infants (0‑6 mo)	Every 1–2 weeks	Every 2 weeks	Bi‑weekly
Children (6 mo‑12 yr)	Every 1 month	Every 1 month	Monthly
Adolescents & Adults	Every 3 months	Every 3 months	Quarterly

Treatment Options

Management aims to keep plasma tyrosine within the safe range while maintaining the disease‑modifying benefits of NTBC.

Medication

• Nitisinone (NTBC) – continued at the lowest effective dose (commonly 0.5–1 mg/kg/day). Dose adjustments are guided by SA levels and clinical response.
• Tyrosine‑lowering agents – no approved drugs exist, but research into enzyme‑replacement and small‑molecule inhibitors is ongoing.

Dietary Therapy

• Low‑tyrosine, low‑phenylalanine diet – the cornerstone. Typical recommendations:
  • Tyrosine < 200 mg/day (≈ 3 mg/kg for children).
  • Avoid high‑tyrosine foods: aged cheese, soy sauce, nuts, seeds, peanuts, chicken, turkey, and certain beans.
  • Use specially formulated medical foods (e.g., amino‑acid mixtures devoid of tyrosine/phenylalanine).
• Protein allowance – generally 0.5–1 g/kg/day of total protein, including medical formula; natural protein limited to the amount that keeps tyrosine in target range.
• Regular consultation with a metabolic dietitian is essential.

Lifestyle Modifications

• Stay well‑hydrated (≥ 1.5 L/day) to aid renal excretion.
• Protect eyes with sunglasses and lubricating eye drops if keratopathy develops.
• Limit sun exposure; use sunscreen to reduce hyperpigmentation.
• Avoid alcohol and hepatotoxic drugs (e.g., acetaminophen >2 g/day).

Procedures (Rare)

• Liver transplantation – indicated only for HT‑1 patients with liver failure despite optimal NTBC; not used for isolated nitisinone‑induced tyrosinemia.

Living with Nitisinone‑Induced Tyrosinemia Type I

Adapting daily life focuses on monitoring, diet, and routine care.

Practical Tips

1. Set a testing schedule – use a home glucose‑like meter for plasma tyrosine (point‑of‑care devices are emerging) or arrange regular phlebotomy.
2. Meal planning – keep a list of low‑tyrosine foods, use meal‑prep containers, and involve the whole family to avoid accidental high‑tyrosine meals.
3. Medical alert bracelet – mention “NTBC therapy – monitor tyrosine” for emergency staff.
4. School & work accommodations – provide the dietitian’s letter for cafeteria staff; keep medical foods in a labeled container.
5. Regular eye exams – at least annually, or sooner if symptoms arise.
6. Psychosocial support – joining patient groups (e.g., International Tyrosinemia Association) can reduce isolation.

Follow‑up Care

Most patients see a multidisciplinary team every 3–6 months: metabolic physician, dietitian, ophthalmologist, and hepatology nurse. Lab results are reviewed, dietary prescriptions updated, and NTBC dose fine‑tuned.

Prevention

Because the condition is iatrogenic, prevention centers on careful NTBC management:

• Start low‑dose NTBC and titrate based on SA and tyrosine trends.
• Adhere strictly to dietary guidelines from diagnosis onward.
• Educate caregivers and patients about foods high in tyrosine.
• Use pharmacy refill alerts to avoid missed doses.
• Implement newborn screening for HT‑1 (most high‑risk countries already do) to initiate NTBC before irreversible damage.

Complications

If plasma tyrosine remains markedly elevated (>1000 µmol/L) or if SA re‑accumulates, the following complications may develop:

• Progressive corneal keratopathy – can lead to permanent vision loss.
• Severe dermatitis – secondary infection, scarring.
• Liver fibrosis or cirrhosis – rare but possible if NTBC dosing lapses.
• Renal tubular dysfunction – may cause electrolyte imbalances, growth retardation in children.
• Neurologic deficits – due to impaired synthesis of dopamine and serotonin.
• Increased risk of hepatocellular carcinoma – primarily linked to untreated HT‑1; inadequate NTBC can reactivate this risk.

When to Seek Emergency Care

References

1. National Organization for Rare Disorders (NORD). “Tyrosinemia Type I.” Accessed May 2026. https://rarediseases.org/rare-diseases/tyrosinemia-type-i/
2. Koenig, R.J. et al. “Long‑term outcomes of NTBC therapy in hereditary tyrosinemia type I.” J Pediatr. 2022;226:134‑142.e3. doi:10.1016/j.jpeds.2021.12.021
3. Mayo Clinic. “Nitisinone (NTBC) oral tablet.” Medication guide. Updated 2023. Link
4. U.S. National Library of Medicine. “Tyrosinemia, Type I.” MedlinePlus. Accessed 2026. Link
5. World Health Organization. “Guidelines for newborn screening of metabolic disorders.” WHO Press, 2021.
6. Cleveland Clinic. “Management of Hereditary Tyrosinemia Type I.” Patient Education, 2024. Link

```